Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR : Expanding the PORD Phenotype
Open accessPublished version of a preprint
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Context: Mutations in cytochrome P450 oxidoreductase (POR) cause a form of congenital adrenal hyperplasia (CAH). We report a novel R550W mutation in POR identified in a 46,XX patient with signs of aromatase deficiency. Objective: Analysis of aromatase deficiency from the R550W mutation in POR. Design, setting, and patient: Both the child and the mother had signs of virilization. Ultrasound revealed the presence of uterus and ovaries. No defects in CYP19A1 were found, but further analysis with a targeted Disorders of Sexual Development NGS panel (DSDSeq.V1, 111 genes) on a NextSeq (Illumina) platform in Madrid and Barcelona, Spain, revealed compound heterozygous mutations c.73_74delCT/p.L25FfsTer93 and c.1648C > T/p.R550W in POR. Wild-type and R550W POR were produced as recombinant proteins and tested with multiple cytochrome P450 enzymes at University Children’s Hospital, Bern, Switzerland. Main outcome measure and Results: POR-R550W showed 41% of the WT activity in cytochrome c and 7.7% activity for reduction of MTT. Assays of CYP19A1 showed a severe loss of activity, and CYP17A1 as well as CYP21A2 activities were also lost by more than 95%. Loss of CYP2C9, CYP2C19, and CYP3A4 activities was observed for the R550W-POR. Predicted adverse effect on aromatase activity as well as a reduction in binding of NADPH was confirmed. Conclusions: Pathological effects due to POR-R550W were identified, expanding the knowledge of molecular pathways associated with aromatase deficiency. Screening of the POR gene may provide a diagnosis in CAH without defects in genes for steroid metabolizing enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Morishima, A., Grumbach, M. M., Simpson, E. R., Fisher, C., & Qin, K. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.12.8530621 · Cited by 1,416
Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome
Flück, C. E., Tajima, T., Pandey, A. V., Arlt, W., Okuhara, K., Verge, C. F., Jabs, E. W., Mendonça, B. B., Fujieda, K., & Miller, W. L. (2004) · Nature Genetics · doi:10.1038/ng1300 · Cited by 509
Self-citationConte, F. A., Grumbach, M. M., Ito, Y., Fisher, C. R., & Simpson, E. R. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.8200927 · Cited by 379
Arlt, W., Walker, E. A., Draper, N., Ivison, H. E., Ride, J. P., Hammer, F., Chalder, S. M., Borucka-Mankiewicz, M., Hauffa, B. P., Malunowicz, E. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16503-3 · Cited by 345
Huang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429417 · Cited by 336
Self-citationMinireview: Regulation of Steroidogenesis by Electron Transfer
Miller, W. L. (2005) · Endocrinology · doi:10.1210/en.2005-0096 · Cited by 324
NADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Pandey, A. V., & Flück, C. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.010 · Cited by 279
Self-citationFlück, C. E., Meyer-Böni, M., Pandey, A. V., Kempná, P., Miller, W. L., Schoenle, E. J., & Biason-Lauber, A. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.009 · Cited by 248
Self-citation
Research works printed but not linked: 42
- Pandey, 2004, P450 oxidoreductase deficiency: a new disorder of steroidogenesis affecting all microsomal P450 enzymes, Endocr Res., 30, 881, 10.1081/ERC-200044134 · DOI · Paper page
- Fukami, 2014, Cytochrome P450 oxidoreductase deficiency: rare congenital disorder leading to skeletal malformations and steroidogenic defects, Pediatr Int., 56, 805, 10.1111/ped.12518 · DOI · Paper page
- Fukami, 2009, Cytochrome P450 oxidoreductase deficiency: identification and characterization of biallelic mutations and genotype-phenotype correlations in 35 Japanese patients, J Clin Endocrinol Metab., 94, 1723, 10.1210/jc.2008-2816 · DOI · Paper page
- Lu, 1969, Resolution of the cytochrome P-450-containing omega-hydroxylation system of liver microsomes into three components, J Biol Chem., 244, 3714, 10.1016/S0021-9258(18)83427-5 · DOI · Paper page
- Murataliev, 2000, Interaction of NADP(H) with oxidized and reduced P450 reductase during catalysis. Studies with nucleotide analogues, Biochemistry., 39, 5066, 10.1021/bi992917k · DOI
- Masters, 2005, The journey from NADPH-cytochrome P450 oxidoreductase to nitric oxide synthases, Biochem Biophys Res Commun., 338, 507, 10.1016/j.bbrc.2005.09.165 · DOI
- Flück, 2011, Clinical and biochemical consequences of p450 oxidoreductase deficiency, Endocr Dev., 20, 63, 10.1159/000321221 · DOI · Paper page
- Flück, 2008, P450 oxidoreductase deficiency - a new form of congenital adrenal hyperplasia, Endocr Dev., 13, 67, 10.1159/000134826 · DOI · Paper page
- Flück, 2007, Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase, Fundam Clin Pharmacol., 21, 399, 10.1111/j.1472-8206.2007.00520.x · DOI · Paper page
- Agrawal, 2010, Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase, Pharmacogenet Genomics., 20, 611, 10.1097/FPC.0b013e32833e0cb5 · DOI · Paper page
- Flück, 2017, Impact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase, J Steroid Biochem Mol Biol., 165, 64, 10.1016/j.jsbmb.2016.03.031 · DOI
- Flück, 2011, Deletion of P399_E401 in NADPH cytochrome P450 oxidoreductase results in partial mixed oxidase deficiency, Biochem Biophys Res Commun., 412, 572, 10.1016/j.bbrc.2011.08.001 · DOI
- Simpson, 1994, Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis, Endocr Rev., 15, 342
- Bilezikian, 1998, Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency, N Engl J Med., 339, 599, 10.1056/NEJM199808273390905 · DOI · Paper page
- Rochira, 2002, Pituitary function in a man with congenital aromatase deficiency: effect of different doses of transdermal E2 on basal and stimulated pituitary hormones, J Clin Endocrinol Metab., 87, 2857, 10.1210/jcem.87.6.8556 · doi:10.1210/jcem.87.6.8556 · Paper page
- Lin, 2007, Variable phenotypes associated with aromatase (CYP19) insufficiency in humans, J Clin Endocrinol Metab., 92, 982, 10.1210/jc.2006-1181 · DOI · Paper page
- Belgorosky, 2009, Genetic and clinical spectrum of aromatase deficiency in infancy, childhood and adolescence, Horm Res., 72, 321
- Bulun, 1994, Regulation of aromatase expression in human tissues, Breast Cancer Res Treat., 30, 19, 10.1007/BF00682738 · DOI
- Shozu, 1991, A new cause of female pseudohermaphroditism: placental aromatase deficiency, J Clin Endocrinol Metab., 72, 560, 10.1210/jcem-72-3-560 · DOI · Paper page
- Bouchoucha, 2014, Characterization of a novel CYP19A1 (aromatase) R192H mutation causing virilization of a 46,XX newborn, undervirilization of the 46,XY brother, but no virilization of the mother during pregnancies, Mol Cell Endocrinol., 390, 8, 10.1016/j.mce.2014.03.008 · DOI
- Stocco, 2012, Tissue physiology and pathology of aromatase, Steroids., 77, 27, 10.1016/j.steroids.2011.10.013 · DOI · Paper page
- Khatri, 2014, Kinetic solvent isotope effect in steady-state turnover by CYP19A1 suggests involvement of compound 1 for both hydroxylation and aromatization steps, FEBS Lett., 588, 3117, 10.1016/j.febslet.2014.06.050 · DOI
- Akhtar, 2015, Acyl-carbon bond cleaving cytochrome P450 enzymes: CYP17A1, CYP19A1 and CYP51A1, Adv Exp Med Biol., 851, 107, 10.1007/978-3-319-16009-2_4 · DOI
- Klein, 2013, Pharmacogenomics of cytochrome P450 3A4: recent progress toward the “missing heritability” problem, Front Genet., 4, 12, 10.3389/fgene.2013.00012 · DOI · Paper page
- Fernández-Cancio, 2019, A novel homozygous AMRH2 gene mutation in a patient with persistent Müllerian duct syndrome, Sex Dev., 13, 87, 10.1159/000499324 · DOI
- Nicolo, 2010, Restoration of mutant cytochrome P450 reductase activity by external flavin, Mol Cell Endocrinol., 321, 245, 10.1016/j.mce.2010.02.024 · DOI
- Udhane, 2017, Altered CYP19A1 and CYP3A4 activities due to mutations A115V, T142A, Q153R and P284L in the human P450 oxidoreductase, Front Pharmacol., 8, 580, 10.3389/fphar.2017.00580 · DOI · Paper page
- Guengerich, 2009, Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase, Nat Protoc., 4, 1245, 10.1038/nprot.2009.121 · DOI · Paper page
- Yim, 2005, A continuous spectrophotometric assay for NADPH-cytochrome P450 reductase activity using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, J Biochem Mol Biol., 38, 366
- Marohnic, 2010, Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect, Drug Metab Dispos., 38, 332, 10.1124/dmd.109.030445 · DOI
- Faeder, 1973, A rapid micromethod for determination of FMN and FAD in mixtures, Anal Biochem., 53, 332, 10.1016/0003-2697(73)90442-9 · DOI · Paper page
- Kagawa, 2011, Efficient expression of human aromatase (CYP19) in E. coli, Methods Mol Biol., 705, 109, 10.1007/978-1-61737-967-3_7 · DOI
- Fernandez-Cancio, 2018, Mechanism of the dual activities of human CYP17A1 and binding to anti-prostate cancer drug abiraterone revealed by a novel V366M mutation causing 17,20 lyase deficiency, Pharmaceuticals, 11, 10.3390/ph11020037 · DOI
- Lephart, 1991, Assay of aromatase activity, Methods Enzymol., 206, 477, 10.1016/0076-6879(91)06116-K · DOI · Paper page
- Velazquez, 2019, Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase, Biochem Biophys Res Commun., 515, 133, 10.1016/j.bbrc.2019.05.127 · DOI
- Flück, 2010, Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism, Biochem Biophys Res Commun., 401, 149, 10.1016/j.bbrc.2010.09.035 · DOI · Paper page
- Reisch, 2019, Alternative pathway androgen biosynthesis and human fetal female virilization, Proc Natl Acad Sci U S A., 116, 22294, 10.1073/pnas.1906623116 · DOI · Paper page
- Miller, 2019, The “backdoor pathway” of androgen synthesis in human male sexual development, Plos Biol., 17, e3000198, 10.1371/journal.pbio.3000198 · DOI
- Baronio, 2019, 46,XX DSD due to androgen excess in monogenic disorders of steroidogenesis: genetic, biochemical, and clinical features, Int. J. Mol. Sci, 20, 4605, 10.3390/ijms20184605 · DOI
- Parween, 2019, Variability in loss of multiple enzyme activities due to the human genetic variation P284T located in the flexible hinge region of NADPH cytochrome P450 oxidoreductase, Front Pharmacol., 10, 1187, 10.3389/fphar.2019.01187 · DOI
- Rochira, 2009, Aromatase deficiency in men: a clinical perspective, Nat Rev Endocrinol., 5, 559, 10.1038/nrendo.2009.176 · DOI · Paper page
- Flück, 2019, Human P450 Oxidoreductase Deficiency., 431, 10.1016/B978-0-12-801238-3.64966-8 · DOI
Cited by
Flück, C. E., Parween, S., Rojas Velazquez, M. N., & Pandey, A. V. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003154117 · Cited by 15
Self-citationRojas Velazquez, M. N., Noebauer, M., & Pandey, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710141 · Cited by 11
Self-citationWang, C., & Tian, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1226387 · Cited by 11
Zhang, C., Zhao, Z., Du, Y., Huang, Q., Liu, Y., Fu, G., & Xu, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1791297
Metadata
- Authors
- Parween, S., Fernández-Cancio, M., Benito-Sanz, S., Camats, N., Rojas Velazquez, M. N., López-Siguero, J.-P., Udhane, S. S., Kagawa, N., Flück, C. E., Audí, L., & Pandey, A. V.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-02-15
- Volume
- 105
- Issue
- 4
- Pages
- e1272-e1290
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W3006451876
- Cited by
- 28
- References
- 32
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Funders
- Swiss National Science Foundation (31003A-134926)
- Novartis Foundation for Medical-Biological Research (18A053)
- Fondo de Investigación Sanitaria (PI05/01647)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR : Expanding the PORD Phenotype. https://app.cochat.ai/papers/10.1210/clinem/dgaa076
- The paper
- Parween, S., Fernández-Cancio, M., Benito-Sanz, S., Camats, N., Rojas Velazquez, M. N., López-Siguero, J.-P., Udhane, S. S., Kagawa, N., Flück, C. E., Audí, L., & Pandey, A. V. (2020). Molecular Basis of CYP19A1 Deficiency in a 46,XX Patient With R550W Mutation in POR : Expanding the PORD Phenotype. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaa076
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.